AI Analysis
AI-generated analysis. Always verify with the original filing.
VistaGen Therapeutics, Inc. disclosed non-compliance with Nasdaq Listing Rule 5605(c)(2) as of April 1, 2026, following the resignation of director Mary Rotunno, reducing its Audit Committee to two members; the company has a cure period to regain compliance.
Key Takeaways
1Audit Committee reduced from three to two members effective April 1, 2026, due to Mary Rotunno’s resignation, triggering non-compliance with Nasdaq Listing Rule 5605(c)(2).
2Non-compliance does not affect current listing of VTGN common stock on The Nasdaq Capital Market.
3Company is granted a cure period expiring earlier of next annual meeting or one year from April 1, 2026 — or 180 days if annual meeting occurs by September 28, 2026.
4Board stated intent to regain compliance with Nasdaq Listing Rule 5605(c)(2) prior to cure period expiration.